Market Overview

Benzinga's Top Initiations

Benzinga's Top Initiations
Related PFE
Will The New Pfizer Be A Winner? SunTrust Analyst Thinks So, Upgrades Stock
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Biotechs Weaken, But These Names Have Bullish Charts (Investor's Business Daily)
Related LNKD
Social Media Shows Off Profit Power
LinkedIn Stock Now Deserves A Higher Multiple, Says MKM's Sanderson
Big-Cap Stocks Hold Sway In A Choppy Market (Investor's Business Daily)

Analysts at Citigroup initiated coverage on shares of Pfizer (NYSE: PFE) with a “buy” rating. Pfizer's shares closed at $24.85 yesterday. Pfizer's trailing-twelve-month operating margin is 31.27%.

Wedbush initiated coverage on shares of LinkedIn (NYSE: LNKD) with a “neutral” rating. LinkedIn's stock closed at $107.11 yesterday. LinkedIn's trailing-twelve-month ROE is 2.76%.

Wells Fargo initiated coverage on shares of Hess (NYSE: HES) with a “market perform” rating. Hess' shares closed at $50.50 yesterday. Hess had $528.00 million in total cash for the recent quarter.

Analysts at Mizuho initiated coverage on shares of Salix Pharmaceuticals (NASDAQ: SLXP) with a “buy” rating. Salix's shares closed at $41.26 yesterday. Salix's PEG ratio is 0.62.

Latest Ratings for PFE

Nov 2015SunTrust Robinson HumphreyUpgradesReduceNeutral
Nov 2015Argus ResearchMaintainsBuy
Oct 2015Cowen & CompanyUpgradesMarket PerformOutperform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings


Related Articles (HES + LNKD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters